INBX
Inhibrx Biosciences, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveInhibrx achieved a major regulatory milestone with FDA acceptance of the ozekibart BLA for chondrosarcoma (PDUFA April 2027), supported by strong Phase 2 efficacy data showing 52% risk reduction in disease progression. The company secured $325M in additional debt financing from Oxford Finance in July 2026, substantially strengthening its cash position to $219.5M and extending runway to execute multiple late-stage trials, including upcoming HNSCC PFS data and new colorectal cancer combination cohorts.
Red flags
- •Negative shareholders' equity and reliance on high-risk external debt financing
- •No product revenue in Q2 2026; company remains pre-commercialization and unprofitable
- •Analyst coverage extremely limited (1–2 analysts); valuation gap between analyst targets (~$277.50) and implied current price (~$80) suggests high execution risk and potential overvaluation in consensus estimates
- •Ozekibart approval not yet assured; BLA acceptance does not guarantee FDA approval by April 2027
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G/A | −78K | 9.3% | +14.0% vs SPY +12.2% abs | 2026-08-14 | ↗ |
| Viking Global | SC 13G/A | — | 10.0% | -16.2% vs SPY -10.7% abs | 2026-05-15 | ↗ |
| Viking Global | SC 13G/A | — | 10.0% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (2)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Viking Global | Andreas Halvorsen | 1.1M | $106M |
| Point72 | Steve Cohen | 26K | $2M |
Quarter-end 13F positions for the tracked funds holding this stock.